Clinical Trial Update: Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating FE 999326 administered intravesically in Japanese patients with high-grade, BCG-unresponsive non-muscle invasive bladder cancer; the tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• FE 999326

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Bladder Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING